Your browser is no longer supported. Please, upgrade your browser.
APLS Apellis Pharmaceuticals, Inc. daily Stock Chart
Apellis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.16 Insider Own3.70% Shs Outstand73.72M Perf Week-1.55%
Market Cap2.38B Forward P/E- EPS next Y-5.71 Insider Trans-0.03% Shs Float58.95M Perf Month2.69%
Income-423.00M PEG- EPS next Q-1.34 Inst Own73.80% Short Float14.83% Perf Quarter15.28%
Sales- P/S- EPS this Y-108.90% Inst Trans24.75% Short Ratio9.12 Perf Half Y-12.53%
Book/sh3.51 P/B9.25 EPS next Y12.80% ROA-90.90% Target Price53.80 Perf Year24.23%
Cash/sh8.83 P/C3.67 EPS next 5Y2.80% ROE-285.80% 52W Range16.85 - 45.04 Perf YTD5.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-27.95% Beta-
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low92.58% ATR1.83
Employees235 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)53.40 Volatility5.60% 5.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-162.20% Profit Margin- Rel Volume0.46 Prev Close31.74
ShortableYes LT Debt/Eq0.56 Earnings- Payout- Avg Volume959.17K Price32.45
Recom1.80 SMA202.74% SMA500.31% SMA2002.87% Volume445,323 Change2.24%
Jun-17-20Initiated BTIG Research Neutral
Apr-01-20Initiated Raymond James Strong Buy $86
Mar-31-20Initiated BMO Capital Markets Outperform $54
Mar-11-20Upgrade Wedbush Underperform → Neutral $29
Jan-07-20Initiated SVB Leerink Mkt Perform $30
Dec-19-19Initiated BofA/Merrill Buy $36
Nov-22-19Initiated Wedbush Underperform
Nov-05-19Initiated Credit Suisse Neutral $33
Aug-01-19Reiterated Cantor Fitzgerald Overweight $52 → $50
Jul-12-19Upgrade JP Morgan Neutral → Overweight $35 → $49
Mar-29-19Initiated Robert W. Baird Outperform $45
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Jul-30-18Upgrade B. Riley FBR Neutral → Buy $27
May-24-18Initiated Cantor Fitzgerald Overweight $52
Apr-12-18Downgrade B. Riley FBR, Inc. Buy → Neutral $27
Feb-08-18Initiated B. Riley FBR, Inc. Buy $27
Jul-07-20 04:05PM  
Jul-02-20 08:00AM  
Jun-16-20 07:00AM  
Jun-12-20 04:23PM  
Jun-10-20 05:34PM  
Jun-05-20 04:05PM  
Jun-04-20 07:00AM  
May-29-20 04:05PM  
May-28-20 07:00AM  
May-21-20 07:00AM  
May-14-20 10:55AM  
May-08-20 07:00AM  
May-07-20 04:05PM  
Apr-29-20 04:11PM  
Apr-28-20 07:00AM  
Apr-07-20 11:33AM  
Apr-06-20 08:00AM  
Feb-27-20 04:44PM  
Feb-26-20 07:00AM  
Feb-06-20 01:23PM  
Jan-16-20 04:30PM  
Jan-15-20 05:39AM  
Jan-13-20 04:57PM  
Jan-09-20 02:18PM  
Jan-08-20 09:30PM  
Jan-07-20 04:15PM  
Jan-02-20 07:00AM  
Dec-09-19 08:48AM  
Dec-06-19 04:11PM  
Nov-26-19 07:00AM  
Nov-15-19 05:30PM  
Nov-08-19 10:00AM  
Nov-07-19 05:30PM  
Nov-05-19 07:30AM  
Oct-28-19 09:26AM  
Oct-16-19 11:43AM  
Oct-11-19 04:01PM  
Oct-04-19 05:30PM  
Oct-03-19 08:37AM  
Sep-27-19 05:30PM  
Sep-26-19 08:00AM  
Sep-18-19 08:00AM  
Sep-16-19 05:00PM  
Sep-13-19 07:31AM  
Sep-12-19 08:22AM  
Sep-11-19 04:38PM  
Sep-09-19 05:00PM  
Sep-03-19 08:00AM  
Aug-28-19 05:00PM  
Aug-25-19 11:31AM  
Aug-16-19 05:00PM  
Aug-02-19 06:00AM  
Jul-31-19 05:00PM  
Jul-26-19 05:30PM  
Jul-22-19 02:34PM  
Jul-18-19 07:00AM  
Jul-14-19 07:03PM  
Jul-12-19 09:42AM  
Jul-08-19 05:30PM  
Jun-27-19 07:39AM  
Jun-19-19 09:31PM  
Jun-15-19 10:00AM  
Jun-06-19 05:30PM  
May-31-19 07:13AM  
May-24-19 05:30PM  
May-13-19 05:30PM  
May-09-19 11:24AM  
May-08-19 07:00AM  
Apr-30-19 01:49PM  
Apr-05-19 04:30PM  
Mar-22-19 04:30PM  
Mar-12-19 06:00PM  
Mar-11-19 04:01PM  
Mar-07-19 07:00AM  
Mar-06-19 04:00PM  
Mar-05-19 11:15AM  
Mar-04-19 04:00PM  
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for intravenous administration in systemic indications. It has a risk-sharing collaboration agreement with SFJ Pharmaceuticals Group for the development of APL-2 in hematologic indications. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grossi FedericoSee RemarksJul 01Sale32.4385027,56630,125Jul 02 05:48 PM